2020 was marked by an unprecedented effort by humanity to combat the coronavirus pandemic (COVID ‑ 19) and was an extremely difficult test for the health systems of all countries. COVID ‑ 19 is an infectious disease caused by the new coronavirus SARS-CoV ‑ 2. The pathophysiology of the infection is associated with an increased inflammatory response of the patient's body, which causes damage not only to lung tissue but also to other body systems, including the cardiovascular system. Current data suggest that 30 to 60% of patients with COVID-19 suffer from coronary heart disease (CHD) and hypertension, ie the presence of a history of cardiovascular disease (CVD) contributes to the fact that patients become more susceptible to COVID ‑ 19.
Acute inflammatory process in the case of COVID ‑ 19 causes worsening of ischemic disorders in the conditions of already existing diseases of the cardiovascular system and provokes a systemic inflammatory response of the body with increasing endothelial dysfunction and procoagulant activity of the blood. Chronic inflammation plays a leading role in the pathogenesis of HF, especially dangerous in COVID ‑ 19 are inflammatory myocardial damage and, as a consequence, acute decompensation of HF on the background of a cytokine storm, during which there is an uncontrolled immune response with activation and proliferation of lymphocytes and lymphocytes. It is quite logical to identify among patients with COVID ‑ 19 people with CVD, including heart failure, with evidence of inflammatory myocardial damage for priority treatment and possibly more aggressive therapy.